CA-DENODO
27.10.2021 09:02:12 CEST | Business Wire | Press release
Denodo , the leader in data virtualization, today announced that its annual global user conference, Denodo DataFest 2021 , which was held in North America (NA), EMEA and APAC, attracted 5,000 worldwide registrants. While DataFest APAC and EMEA were held in a virtual format this year, DataFest NA was conducted in a hybrid mode, attracting hundreds of attendees online and in-person in New York. The attendees, made up of Denodo customers, partners, and subject matter experts, discussed the future of data and analytics involving topics such as logical data fabric, cloud modernization, data mesh, AI/ML and more.
Forrester VP and Principal Analyst Michele Goetz kicked off the conference presenting the Total Economic Impact™ of Data Virtualization using Denodo Platform , while David Loshin, President of Knowledge Integrity at TDWI presented the importance of Logical Data Fabric for Hybrid Cloud. Click here to watch the full conference line up.
“While we are not entirely over the pandemic yet, I was personally touched and thrilled to see the excitement among our customers and partners, both in-person and online who joined us to make this year’s DataFest such a success,” said Ravi Shankar, SVP and CMO at Denodo. “Our customers, partners, and internal subject matter experts presented and discussed topics such as why data lakehouse needs a logical architecture, application of advanced semantics in multi/hybrid cloud scenarios, the need for performance acceleration for advanced analytics and data science, to name a few. It was great to see the strength of our customers’ use cases as the Innovation Award polling saw stiff competition among the finalists.”
Winners and Finalists of Denodo Data Innovation Awards 2021 include:
- North America – Winner Ryan Fattini from City Furniture , for their Digitizing City Furniture’s Business Model use case; finalist Jonathan Paul from Fifth Third Bank , for their Digital Transformation and Regulatory Excellence use case.
- APAC – Winner Shaurya Bhasin from GeTS , for their Logical Data Fabric use case; finalist Wilbertus Darmadi from Toyota Astra Motor , for their Data Catalog based Self-Service use case.
- EMEA – Winner Jan Swanepoel from NedBank , for their Largest Data Warehouse on the Planet use case; finalist, Luis Guadarrama from Engie for their data-driven initiatives with Logical Data Fabric use case.
“Winning this year’s Data Innovation Award for the APAC region was a great validation of the strength of our data virtualization use cases and the results we were able to achieve,” said Shaurya Bhasin, Data Platform Lead at GeTS. “In building our unified data platform we were able to offer secure and well governed data access in a multi-cloud scenario. The Denodo Platform is as an important piece of the architecture and I was happy to share our story with the DataFest audience and perhaps it resonated with the audience!”
While Denodo customers played a pivotal role in sharing their business and technical use cases with the audience, it was the amazing network of Denodo Partners which included Accenture, Advanced Analytic Service, Axians, BDO (SimplicityBI), BITanium, CIO Academy Asia (CIOAA), Cognizant, Cyberionix, Dai Nippon Printing, DAMA, Devfacto, EY, Hitachi Solutions, Indium Software, Insight Technology, iOCO, IQZ Systems, JEMS, Mainline, MDI Novare Technologies, Nippon Systemware, NS Solutions, Nucleus Software, Q Perior, Servian, Sirius, UST, Wipro and Zeal that made an event of this scale possible. Denodo’s technology partner AWS took part in a Fireside chat to discuss the important of Logical Data Fabric for successful cloud migration.
Please tweet: #datavirtualization leader Denodo announce the winners of 4th annal Data Innovation Awards During #DataFest 2021. Audience vote @CityFurniture, @CLGeTS and @Nedbank for the most innovative use cases
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom